Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for older adults and people with disabilities.

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated prices for Ozempic, Wegovy, and Rybelsus will be. In Medicare's negotiations ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The next round of Medicare's historic drug price negotiations could save billions for seniors taking medications like Ozempic ...

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in ...

Medicare will continue to negotiate drug prices in 2025. (HealthDay News) — Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people with ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate prices concessions, Bloomberg reported. The company told USA TODAY that it would ...

Coverage of obesity drugs in health plans and the rapid adoption of artificial intelligence are two areas of change that health plans will face during the coming year. A panel of Avalere experts ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden ...

The drugs identified for negotiation in the second round include: Ozempic, Wegovy and other GPL-inhibitors are in high demand in the U.S. Due to that demand, Medicare covering them for diabetes ...